Robocath

Robocath and MicroPort, through its subsidiary MedBot, finalized a joint venture to commercialize Robocath's R-One robotic-assisted platform in China. Robocath holds 49% and MedBot 51% of the joint venture.

MicroPort MedBot and Robocath have executed definitive agreements to form a joint venture for vascular robotics in China. MedBot will own 51% and Robocath 49%.

MicroPort Scientific Corporation led a strategic investment of up to €40 million in Robocath and signed a binding term sheet to form a China-based joint venture for vascular robotics.

MicroPort and Robocath signed a binding term sheet to establish a China-based joint venture to obtain regulatory approval, manufacture, and commercialize Robocath's R-One robotic system in Greater China. MicroPort will invest €5.1 million for 51% stake, Robocath €4.9 million for 49%.

MicroPort Medical announced its subsidiary will invest up to €25.3 million in Robocath, a French vascular robotics company, for a 23.19% stake. The parties also plan to form a joint venture in China to commercialize Robocath's R-One system.